Jogender Tushir-Singh, Assistant Professor of Biochemistry and Molecular Genetics, and his team published research findings that evaluate and improve immunotherapies for treating solid cancer tumors, such as ovarian, colon and triple-negative breast cancer. Initially, these immunotherapies, which had shown promising lab test results, failed in human clinical trials, but Tushir-Singh’s research could shed light on the cause of these failures and help improve future cancer treatments. Tushir-Singh’s research received NIH funding and has been featured in multiple international publications.
March 2021-EVP’s List-Dr. Jogender Tushir-Singh
April 30, 2021 by email@example.com